-The Hindu The public transport system is the most effective way of reducing the number of vehicles as well as emissions Prime Minister Manmohan Singh recently launched the National Electric Mobility Mission Plan (NEMMP), 2020 with an ambitious goal of shifting to electric propulsion for surface transport. This would reduce our dependence on diesel and petrol and lead to lower emission levels, including carbon-di-oxide emission, which is one of the major contributors...
More »SEARCH RESULT
Total Matching Records found : 402
Has India lost the 21st century?-Avalok Langer
-Tehelka With 65 percent of the population below the age of 35, India boasts of an unparalleled generational dividend, but are we turning this potential into a disaster? Avalok Langer spots a ticking time bomb Nutrition & Health* 40% of children in India are malnourished 43% of children in the age group of 12-23 months receive full immunisation 48%+ of children are underweight 50%+ of all deaths under age 5 are related to malnutrition 45% of children...
More »What Right To Education? Failing to meet the prescribed norms, half of the existing schools will lose their recognition -Arvind Panagariya
-The Times of India The three-year compliance period for the Right to Education (RTE) Act is just over. What has the Act accomplished? Sadly, not very much that is positive. A key provision in the law abolishes board examinations and grants automatic promotion to each child to the next grade at the end of the academic year. It also requires the award of a diploma to all at the end of eight...
More »Patent justice-Sakthivel Selvaraj
-The Hindu Drug patents are designed to create profits that enable more research on diseases affecting millions. But in practice, they have often generated super profits for big pharma companies while erecting access barriers for the poor. The Novartis case spotlights much that is wrong with the system. The rejection of the Novartis petition challenging one of the most progressive tenets of the Indian Patents Act (1970), as amended in 2005 by...
More »SC’s Glivec ruling setback to foreign pharma firms -Vidya Krishnan and CH Unnikrishnan
-Live Mint SC rejects Novartis's patent plea for Glivec, says it does not meet any standard of novelty or inventiveness In a landmark judgement, India's apex court rejected Swiss drug maker Novartis AG's legal challenge aimed at securing a patent for blockbuster anti-cancer drug imatinib mesylate, branded Glivec in the country. The verdict, which is seen as a setback to multinational pharmaceutical companies operating in India, may influence a rash of pending disputes...
More »
